News

In the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies, 1,035 patients with genotype 1-6 HCV infection received 12 weeks of SOF/VEL. Among these patients, 21 percent had compensated cirrhosis and

The company said the drug is better than a placebo in reducing pain in patients undergoing bunionectomy. The company carried out the randomized, placebo-controlled, double-blind study in 64

The proceeds will enable Deciphera to advance its pipeline of proprietary switch control kinase inhibitors through multiple key clinical milestones. Concurrent with the financing, Liam Ratcliffe, M.D., Ph.D.,

The company carried out the worldwide Phase III RECOURSE trial in 800 patients who were earlier treated for mCRC. It met the primary efficacy endpoint of statistically significant

The US Food and Drug Administration (FDA) has approved Perrigo’s generic version of Valeant Pharmaceuticals’ BenzaClin Topical Gel. The commercial launch will start immediately. The FDA concluded that

Novo Nordisk Iran and the Food and Drug Administration of the Islamic Republic of Iran have signed a Memorandum of Understanding for the project, which is expected to

Gerilimzumab is directed against the IL-6 cytokine. The double-blinded and placebo controlled trial includes single and multiple ascending dose cohorts. RuiYi plans to release the trial’s results in

Headquartered in Miami, Synowledge specializes in pharmacovigilance, regulatory affairs and information technology services to support biopharmaceutical companies with recording, analyzing and reporting adverse drug events. BioClinica president and

The study, published in The American Journal of Managed Care, suggests that this approach may help quickly identify those patients most likely to benefit from medication adherence interventions.